

Research Article

Urinary 6-Sulphatoxymelatonin Levels and Risk of Breast Cancer in Premenopausal Women: The ORDET Cohort

Eva S. Schernhammer^{1,2,3}, Franco Berrino⁴, Vittorio Krogh⁵, Giorgio Secreto⁴, Andrea Micheli⁶, Elisabetta Venturelli⁴, Sara Grioni⁵, Christopher T. Sempos⁷, Adalberto Cavalleri⁴, Holger J. Schünemann^{7,10,8}, Sabrina Strano⁹, and Paola Muti⁸

Abstract

Background: Lower urinary melatonin levels are associated with a higher risk of breast cancer in postmenopausal women. Literature for premenopausal women is scant and inconsistent.

Methods: In a prospective case-control study, we measured the concentration of 6-sulphatoxymelatonin (aMT6s) in the 12-hour overnight urine of 180 premenopausal women with incident breast cancer and 683 matched controls.

Results: In logistic regression models, the multivariate odds ratio (OR) of invasive breast cancer for women in the highest quartile of total overnight aMT6s output compared with the lowest was 1.43 [95% confidence interval (CI), 0.83-2.45; $P_{\text{trend}} = 0.03$]. Among current nonsmokers, no association was existent (OR, 1.00; 95% CI, 0.52-1.94; $P_{\text{trend}} = 0.29$). We observed an OR of 0.68 between overnight urinary aMT6s level and breast cancer risk in women with invasive breast cancer diagnosed >2 years after urine collection and a significant inverse association in women with a breast cancer diagnosis >8 years after urine collection (OR, 0.17; 95% CI, 0.04-0.71; $P_{\text{trend}} = 0.01$). There were no important variations in ORs by tumor stage or hormone receptor status of breast tumors.

Conclusion: Overall, we observed a positive association between aMT6s and risk of breast cancer. However, there was some evidence to suggest that this might be driven by the influence of subclinical disease on melatonin levels, with a possible inverse association among women diagnosed further from recruitment. Thus, the influence of lag time on the association between melatonin and breast cancer risk needs to be evaluated in further studies. *Cancer Epidemiol Biomarkers Prev*; 19(3); 729-37. ©2010 AACR.

Introduction

Secretion of melatonin, an indoleamine hormone that is produced primarily by the pineal gland, follows a rhythm of ~24 hours with most production occurring during the dark phase of a light-dark cycle (1). Circadian, that is ~24-hour, rhythms (2) drive some of the most important biological functions in humans and are reg-

ulated by a circadian pacemaker located in the hypothalamus (3), of which melatonin is thought to be a surrogate marker. The urine concentration of the major metabolite of melatonin, 6-sulphatoxymelatonin (aMT6s), is highly correlated with melatonin levels in blood and saliva (4-10).

Results of previous studies (reviewed in ref. 11) suggest that night-shift work, a surrogate for exposure to light at night, is associated with an increased risk of breast cancer (12). Following earlier suggestions by Cohen et al. of a role of melatonin in the induction of breast tumors (13) and on the basis of results of laboratory and animal experiments (14-16), light-induced suppression of melatonin secretion has been hypothesized as the major cause of this association; however, although associations among postmenopausal women consistently suggest a lower risk of breast cancer with higher melatonin levels (17, 18), the only two prospective studies conducted to date to study associations between circulating melatonin and premenopausal breast cancer risk showed inconsistent results: one study found no evidence that 24-hour urinary levels of melatonin are strongly associated with the risk of breast cancer (19), whereas the other study reported their first morning urinary levels of melatonin to be strongly and inversely related to risk of breast cancer (20).

Authors' Affiliations: ¹Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School and ²Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; ³LBI-ACR-CTO & ACR-ITR VIENNA/CEADDP, Vienna, Austria; ⁴Department of Preventive and Predictive Medicine, ⁵Nutritional Epidemiology Unit, and ⁶Descriptive Epidemiology and Health Planning Unit, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy; ⁷Department of Social and Preventive Medicine, SPHPS, University of Buffalo, Buffalo, New York; ⁸Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Canada; and ⁹Molecular Chemioprevention Unit, Scientific Director Department and ¹⁰Istituto Nazionale Tumori Regina Elena Istituto Di Ricovero e Cura a Carattere Scientifico, Rome, Italy

Corresponding Author: Eva S. Schernhammer, Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115. Phone: 617-525-4648; Fax: 617-525-2008. E-mail: eva.schernhammer@channing.harvard.edu

doi: 10.1158/1055-9965.EPI-09-1229

©2010 American Association for Cancer Research.

We used a nested case-control design to conduct a prospective study of the association between melatonin levels in 12-hour overnight urine and breast cancer risk in a large cohort of premenopausal women enrolled in *Hormones and Diet in the Etiology of Breast Cancer Risk* (ORDET). We evaluated associations between total aMT6s produced between 7:00 p.m. and 7:00 a.m. and creatinine-adjusted aMT6s measured in overnight urine and premenopausal breast cancer risk.

Materials and Methods

The ORDET cohort was established in Northern Italy between June 1987 and June 1992, when 10,786 healthy women ages 35 to 69 y were enrolled (21, 22). They were all residents of the Varese province, an area covered by the Lombardy Cancer Registry (23), who had heard about the study through the media, at public meetings, and at breast cancer early detection centers, and who volunteered to participate. At recruitment, several baseline characteristics including demographics and dietary intake were queried from each participant through questionnaire; direct measurements of several anthropometric variables including height and weight were conducted; and blood and urine specimens were collected. Because of the focus of the study on endogenous hormones and their relationship with breast cancer risk, stringent inclusion criteria were established and highly standardized conditions on collecting biological samples were applied. Women were excluded if they reported a bilateral ovariectomy, were currently breast feeding or pregnant, used oral contraceptives or hormone replacement therapy in the last 3 mo, were affected by chronic or acute liver disease, or reported a history of cancer.

Cancer incidence information, available from the local cancer registry (Varese Cancer Registry) was linked to the ORDET cohort to identify incident breast cancer cases up to December 2003. The Varese Cancer Registry is of high quality: <2% of breast cancer cases are known to the registry by death certificate only, and the histology and cytology of 96.3% of all cases has been confirmed through pathology reports (21, 24). The ORDET file was also linked to the Varese residents' file to check the participants' vital status.

After exclusion of women with a history of cancer (with the exception of nonmelanoma skin cancer) and women who, immediately after baseline, were lost to follow-up (observed time, 0), 10,633 participants remained to form the base population of ORDET. For this study, we further restricted the ORDET cohort to its 6,667 premenopausal participants. Women were considered premenopausal when they reported having any menstrual cycle over the past 12 mo. Participants were censored at the time of cancer diagnosis, death, or loss to follow-up, whichever came first (median follow-up time, 15.4 y).

Selection of Case and Control Subjects

Case and control subjects were selected from among all 6,667 eligible premenopausal women. Case subjects were

women who developed breast cancer after their recruitment into the ORDET cohort but before the end of the study period (December 31, 2003). We identified a total of 238 incident breast cancer cases. Of these, 58 women were eliminated because their follicle-stimulating hormone level was indicative of perimenopausal or postmenopausal status (that is, follicle-stimulating hormone of >10 $\mu\text{L/mL}$). Of the remaining 180 cases, 10 had *in situ* breast cancer.

For each case subject with breast cancer, four control subjects were randomly chosen from appropriate risk sets consisting of all cohort members who satisfied the matching criteria (age at recruitment of ± 3 y, date of recruitment of 180 d, and laboratory batch) and were alive and free of cancer (except nonmelanoma skin cancer) at the time of diagnosis of the index case. Matching characteristics were age (± 3 y) at enrollment, date of recruitment (± 180 d), and laboratory batch. A total of 683 controls were selected. An incidence density sampling protocol for control selection was used, such that controls could include subjects who became a case later (13 women), whereas each control subject could also be sampled more than once (77 women).

Specimen Collection

Women were instructed to collect their urine over the previous night. They followed a collection protocol that called for discarding the last void at 7:00 p.m. and collecting urine during the night up to 7:00 a.m. Urines were collected during the luteal phase of a woman's menstrual cycle, between day 20 and 24. Overnight urine was kept at room temperature during collection. After delivery to the ORDET recruitment center the day after overnight collection between 7:30 a.m. and 9:00 a.m., all urine samples were immediately processed and stored at -80°C until biochemical determinations were done. Urine was filtered and separated, and 2-mL aliquots were stored. No preservatives were added either at collection or during storage. Similarly, blood samples were collected during the luteal phase of a woman's menstrual cycle, between day 20 and 24, after overnight fasting between 7:30 a.m. and 9:00 a.m. and stored at -80°C . This study was approved by the Ethical Review Board of the National Cancer Institute of Milan (Italy).

Laboratory Methods

Stability and reliability of the ORDET collection method for aMT6s have been shown (25) to be reasonable, although storage temperature affected specimens such as that urine stored long term at -30°C had systematically lower aMT6s levels than urine stored at -80°C .

Urine samples from breast cancer cases and related controls were handled identically and assayed together on the same day and in the same run. All samples were taken out of the freezer simultaneously and sent to the laboratory in the same parcel on dry ice. They were stored at -80°C for an average of 17 y. Laboratory personnel were blinded to case-control status. Control

of analytic error was based on the inclusion of two standard samples.

Urinary aMT6s was assayed by the Hormone Research Laboratory, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori (Milan, Italy), using the Bühlmann ELISA EK-M6S (Bühlmann Laboratories AG) with a lower detection limit of 0.8 ng/mL for aMT6s.

Creatinine levels were also measured for each sample by the Medical Laboratory of the Department of Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori (Milan, Italy), with a Hitachi Modular Automatic Analyzer and optimized reagents (F. Hoffmann, La Roche Ltd; ref. 26). The average between-batch coefficient of variation was 5.3% and 10.3% for urinary aMT6s [high and low standard quality controls (QCs)], and 2.7% and 2.1% for creatinine concentrations of 1.2 and 4.37 mg/dl, respectively. The within-batch coefficient of variations (CVs) derived from the quality control urine included in the analytic runs were 1.8% and 9.8% for aMT6s (high and low standard QCs).

Plasma sex steroid measurements (testosterone, free testosterone, Sex hormone-binding globulin (SHBG), and estradiol) were conducted by Centro Medico Diagnostico Emilia (Bologna, Italy). For testosterone and free testosterone, we used Coat-A-Count procedure, a solid-phase RIA (Diagnostic Product Corp.); for SHBG, we used IMMUNOLITE 1000 Analyzer, a solid-phase, chemiluminescent immunometric assay (Diagnostic Product Corp.); and for estradiol, we used Orion Diagnostica SPECTRIA Estradiol *Sensitive* RIA test, a coated tube RIA (Orion Diagnostica Oy). Quality control was done at three concentrations for sex hormone binding globulin (SHBG) and total and free testosterone and at four concentrations for total estradiol. In each batch, quality control samples were evaluated in quadruplicates. Within-batch quality control coefficients of variation were 5.9% (high concentration) and 14.0% (low concentration) for estradiol; 5.8% and 10.6%, respectively, for total testosterone; 7.0% and 9.6%, respectively, for free testosterone; and 3.1% and 3.4%, respectively, for SHBG. Average between-batch coefficients of variation were 7.4% (high) and 16.4% for estradiol (low), 8.7% and 18.5% for total testosterone, 14.9% and 17.2% for free testosterone, and 4.9% and 4.6% for SHBG.

Statistical Analyses

In total, 180 case patients with invasive or *in situ* breast cancer and 683 matched control subjects were available for our analyses. We multiplied aMT6s concentration (ng/mL) with 12-h urine volume to obtain total aMT6s produced between 7:00 p.m. and 7:00 a.m. (reported as microgram per 12 h). In secondary analyses, aMT6s levels were normalized to the creatinine level of the sample to account for differences arising from variations in urine concentrations (reported as ng aMT6s per milligram of creatinine).

To test for the differences in hormone levels between case and control subjects, we used mixed-effects regression models for clustered data to adjust for possible confounding due to the matching factors and for any residual correlation between case and control subjects within the matched set (27). We used conditional regression models to estimate the relative risks of breast cancer [reported as odds ratios (OR) with 95% confidence intervals (CI)] by quartiles of urinary aMT6s concentrations, which were defined on the basis of the values for all control subjects. Multivariate models were adjusted for known risk factors for breast cancer [see footnote to Table 3]. In secondary analyses, we also adjusted for the sex steroids that we measured in our data set. We tested for trends by modeling natural aMT6s concentrations continuously and calculating the Wald statistic. To evaluate the presence of an interaction between smoking (binary; current versus past or never smokers) and aMT6s levels (continuously), we added an interaction term into our logistic regression model and used the likelihood ratio test for interaction to determine significance. We used the SAS version 9.1.3 for all analyses. All *P* values were two sided.

Results

Table 1 shows baseline characteristics of the 180 cases and 683 controls. The mean time between urine collection and diagnosis was 7.7 years (89 months; SD, 50.5) with a range of 1 to 185 months. Study participants were all premenopausal with an age range of 35 to 54 years at urine collection. Most of the women's baseline characteristics did not differ by case-control status (Table 1). However, age-adjusted mean urinary aMT6s concentration of the breast cancer cases was slightly higher than that of controls [17.4 µg aMT6s versus 15.8 µg aMT6s; 29.3 ng aMT6s/mg creatinine versus 27.6 ng aMT6s/mg creatinine]. Table 2 shows age and age-adjusted baseline characteristics by quartiles of urinary overnight aMT6s (microgram) among the 683 controls included in this study. Several of the women's baseline characteristics, including age, family history of breast cancer, history of benign breast disease, smoking, and body mass index (BMI), differed modestly by aMT6s quartile (Table 2). From among several sex steroids, including circulating plasma testosterone, free testosterone, SHBG, and estradiol, none seemed to vary substantially by aMT6s level.

Overall, we observed a positive association between urinary aMT6s concentrations and breast cancer risk (OR for highest versus lowest quartile of urinary aMT6s concentration, 1.53; 95% CI, 0.91-2.56; $P_{\text{trend}} = 0.01$; Table 3), which was modestly attenuated after additional adjustment for breast cancer risk factors including current smoking status (OR, 1.43; 95% CI 0.83-2.45). Night work and melatonin have been more strongly related to invasive than *in situ* breast cancer risk (20, 28-30), and we, therefore, excluded 10 cases who were diagnosed with *in situ* breast cancer and their matched controls. Among women with

Table 1. Baseline characteristics of 180 premenopausal women with invasive ($n = 170$) or *in situ* ($n = 10$) breast cancer and their 683 matched controls

All women	Cases ($n = 180$)	Controls ($n = 683$)
Age, y	43.4 (4.3)	43.1 (4.3)
Urinary aMT6s, ng/mL creatinine	29.3 (1.11)	27.6 (0.57)
Urinary aMT6s/12 h, μg	17.4 (0.61)	15.8 (0.31)
Age at menarche, y	12.6 (1.4)	12.6 (1.4)
Parity (among parous women only; %)	1.9 (0.8)	2.0 (0.8)
Age at first birth (among parous women only)	22.8 (9.4)	22.7 (9.0)
Family history of breast cancer (%)	9.4	7.6
OC use (%)	45.3	41.9
BMI, kg/m^2	24.3 (4.4)	24.4 (4.0)
Alcohol consumption, g/d	9.4 (13.0)	8.8 (12.8)
History of benign breast disease (%)	31.1	27.2
Education beyond 8 y of elementary school (%)	41.7	31.7
Smoking history		
Current smoker (%)	20.0	24.5
Past smoker (%)	20.0	12.5
Never smoker (%)	60.0	63.0
Pack-years among ever smokers	9.6 (9.0)	9.4 (10.1)
Sex hormone levels		
SHBG (nmol/L)	65.7 (2.1)	67.3 (1.1)
Testosterone (ng/mL)	0.29 (0.01)	0.28 (0.06)
Free testosterone (pg/mL)	0.71 (0.03)	0.69 (0.02)
Estradiol (pg/mL)	90.8 (3.9)	95.3 (2.0)
FSH ($\mu\text{g}/\text{mL}$)	4.1 (0.12)	4.0 (0.06)
LH ($\mu\text{g}/\text{mL}$)	2.5 (0.14)	2.7 (0.07)

NOTE: Mean (SD) of Baseline characteristics of 180 premenopausal women was shown and their 683 controls. Abbreviation: OC, oral contraceptive; FSH, follicle-stimulating hormone; LH, luteinizing hormone.

invasive breast cancer only, the association was very similar (multivariate OR for highest versus lowest quartile of urinary aMT6s concentration, 1.39; 95% CI, 0.90-2.41; $P_{\text{trend}} = 0.04$) and we therefore kept these 10 cases in all subsequent analyses.

When we evaluated the influence of sex steroid hormones on these associations, none of the hormones previously found to predict premenopausal breast cancer risk was correlated with urinary aMT6s to a meaningful degree (all Spearman rank correlations ≤ 0.08 : $r = -0.08$, $P = 0.02$ for testosterone; $r = 0.02$, $P = 0.49$ for free testosterone; $r = -0.06$, $P = 0.11$ for estradiol; and $r = -0.01$, $P = 0.85$ for SHBG). Further adjustment for testosterone, free testosterone, estradiol, or SHBG in our multivariate regression models did not alter our estimates substantially (data not shown).

Based on a previous study suggesting that the nocturnal plasma melatonin increase inversely correlates with tumor estrogen receptor (ER) concentration (31), we conducted analyses stratified on ER status. For 169 of all 180 premenopausal breast cancer cases, hormone receptor status was available, and for 164 cases, HER2 status was available. Of these, 66.9% were ER-positive tumors

(only 56 women had ER-negative breast tumors), and 79.3% were HER2 negative (only 34 women had HER2-positive breast tumors). When we restricted the analysis to women with ER-positive breast tumors, the positive association between aMT6s and breast cancer risk was virtually the same (multivariate OR for highest versus lowest quartile of urinary aMT6s, 1.44; 95% CI, 0.67-3.08) and remained by and large unchanged when we restricted to women with HER2-negative tumors (multivariate OR for highest versus lowest quartile of urinary aMT6s, 1.84; 95% CI, 0.94-3.60). Similarly, although based on only 19 cases in the upper quartile, the risk of ER-negative breast cancer seemed highest among women in the highest quartile of aMT6s (OR, 2.16; 95% CI, 0.78-6.00).

We found no effect modification by age (stratified along the median, ages <43 and ≥ 43 years) or BMI (stratified along the median, 24.4). Because a previous study suggested that cigarette smoking affects melatonin production in premenopausal women (32), we further stratified by smoking status. Among never or past smokers, we observed no association between urinary melatonin levels and breast cancer risk (highest versus lowest quartile of urinary aMT6s concentration, 1.00; 95% CI, 0.52-1.94;

$P_{\text{trend}} = 0.29$; Table 3). By contrast, we observed a positive association among women who reported cigarette smoking at the time of urine collection [highest versus lowest quartile of urinary aMT6s concentration, age-adjusted OR, 2.84; 95% CI, 0.43-18.8; $P_{\text{trend}} = 0.14$; χ^2 from Log-likelihood (LLH) ratio test for interaction between smoking and aMT6s, 1.22, P (1 degree of freedom) = 0.27], although power was limited in these analyses with only 36 breast cancer cases among current smokers.

Next, to rule out the possibility of preclinical tumors influencing our aMT6s levels, we excluded cases that were diagnosed shortly after urine collection, using a stepwise approach (Table 3). In these analyses, the association between urinary aMT6s level and breast cancer risk became increasingly inverse after excluding case patients who were diagnosed with invasive breast cancer within 2 years (OR for highest versus lowest quartile of urinary aMT6s concentration and risk of breast cancer developed at least >2 years after urine collection, 0.68; 95% CI, 0.32-1.44; $P_{\text{trend}} = 0.63$), 4 years (OR for highest versus lowest quartile of urinary aMT6s concentration, 0.61; 95% CI, 0.26-1.39; $P_{\text{trend}} = 0.80$), or 8 years after urine collection (OR for highest versus lowest quartile of urinary aMT6s concentration, 0.17; 95% CI, 0.04-0.71;

$P_{\text{trend}} = 0.01$), although the latter analysis was based on 12 cases only in the upper quartile. By contrast, when restricting to women who developed breast cancer within 3 years after urine collection (28 cases; there were only 14 and 24 cases diagnosed within 1 and 2 years after urine collection, respectively, limiting our power to explore these associations), the association with breast cancer risk was strongly positive among those with the highest melatonin levels (OR for highest versus lowest quartile of urinary aMT6s concentration, 14.8; 95% CI, 1.39-157; $P_{\text{trend}} = 0.03$). The lack of an association between melatonin and breast cancer risk that we observed in the overall data set (that is, including past and current smokers) remained unchanged throughout these secondary analyses when smokers were included (data not shown). Of all tumors, 92 were histopathologically classified as localized and 51 as metastatic—the remaining 27 were of unknown tumor stage. Further analyses stratifying by localized versus metastasized breast tumors did not reveal any effect modification by tumor stage (data not shown).

In secondary analyses, we also evaluated associations between creatinine-adjusted aMT6s and breast cancer risk. Creatinine-adjusted and total aMT6s were highly correlated (Spearman $r = 0.75$, $P < 0.001$) and both measures

Table 2. Age and age-adjusted baseline characteristics of 683 controls by quartiles of urinary aMT6s level

All control women	Quartiles of 12-h overnight urinary aMT6s output (μg)			
	Q1 (n = 170)	Q2 (n = 171)	Q3 (n = 172)	Q4 (n = 170)
Range of urinary aMT6s output/12 h (μg)	<10.1	10.1-14.6	14.7-20.5	≥ 20.6
Age, y	43.8	43.0	42.4	43.3
Age at menarche, y	12.8	12.6	12.6	12.5
Parity (no. of children, among parous women only)	2.1	2.0	1.9	1.9
Age at first birth (among parous women only)	25.4	24.9	26.1	26.1
Family history of breast cancer (%)	8.8	7.0	5.8	8.8
OC use (%)	38.9	45.9	37.7	47.7
BMI, kg/m^2	24.6	24.4	24.5	24.2
Alcohol consumption, g/d	8.0	7.8	11.7	7.7
History of benign breast disease (%)	29.4	29.8	25.6	24.1
Education beyond 8 y of elementary school (%)	31.9	28.6	30.2	35.9
Smoking history				
Current smoker (%)	27.1	24.0	24.4	22.4
Past smoker (%)	6.5	14.0	14.0	15.3
Never smoker (%)	66.5	62.0	61.6	62.4
Pack-years among ever smokers	12.9	9.8	7.5	7.9
Sex hormone levels				
SHBG (nmol/L)	64.7	68.6	68.2	67.8
Testosterone (ng/mL)	0.30	0.29	0.29	0.25
Free testosterone (pg/mL)	0.72	0.68	0.70	0.65
Estradiol (pg/mL)	98.1	97.7	95.4	90.1
FSH ($\mu\text{g}/\text{mL}$)	4.1	4.1	4.0	3.7
LH ($\mu\text{g}/\text{mL}$)	2.8	3.0	2.8	2.3

NOTE: Mean of age and other baseline characteristics are shown.

Table 3. ORs and 95% CIs of breast cancer by quartile of total 12-h overnight aMT6s output [aMT6s concentration (ng/mL) multiplied with 12-h volume in mL]

Group and parameter	Quartile				<i>P</i> _{trend} *
	1	2	3	4	
Urinary aMT6s output/12 h (μg)	<10.1	10.1-14.6	14.7-20.5	≥20.6	
No. of case patients/no. of control subjects	39/170	34/171	55/172	52/170	
Invasive and <i>in situ</i> breast cancer cases					
Simple OR*	1.00 (Reference)	0.91 (0.54-1.53)	1.50 (0.92-2.45)	1.53 (0.91-2.56)	0.01
Multivariate OR†	1.00 (Reference)	0.88 (0.51-1.50)	1.43 (0.85-2.42)	1.43 (0.83-2.45)	0.03
Excluding current smokers					
No. of case patients/no. of control subjects	32/96	27/107	44/106	41/114	
Simple OR†	1.00 (Reference)	0.75 (0.41-1.36)	1.24 (0.70-2.20)	1.16 (0.63-2.15)	0.19
Multivariate OR‡	1.00 (Reference)	0.72 (0.38-1.38)	1.11 (0.59-2.08)	1.00 (0.52-1.94)	0.29
Multivariate lagtime analyses among nonsmokers					
No. of case patients/no. of control subjects	5/35	4/29	8/33	11/35	
Multivariate OR‡ among women diagnosed within 3 y from urine collection	1.00 (Reference)	0.90 (0.09-8.75)	1.88 (0.23-15.3)	14.8 (1.39-157)	0.03
No. of case patients/no. of control subjects	30/73	24/82	41/81	35/89	
Multivariate OR‡ 1 y lag time	1.00 (Reference)	0.61 (0.30-1.23)	1.07 (0.54-2.12)	0.90 (0.45-1.82)	0.40
No. of case patients/no. of control subjects	28/65	24/79	38/75	30/83	
Multivariate OR‡ 2 y lagtime	1.00 (Reference)	0.58 (0.28-1.19)	0.95 (0.47-1.94)	0.68 (0.32-1.44)	0.63
No. of case patients/no. of control subjects	27/61	23/78	36/73	30/79	
Multivariate OR‡ 3 y lagtime	1.00 (Reference)	0.51 (0.24-1.08)	0.87 (0.42-1.82)	0.69 (0.32-1.48)	0.52
No. of case patients/no. of control subjects	24/53	19/73	33/67	28/68	
Multivariate OR‡ 4 y lag time	1.00 (Reference)	0.41 (0.18-0.92)	0.76 (0.34-1.66)	0.61 (0.26-1.39)	0.80
No. of case patients/no. of control subjects	23/52	19/64	28/65	27/62	
Multivariate OR‡ 5 y lag time	1.00 (Reference)	0.47 (0.20-1.09)	0.66 (0.29-1.48)	0.66 (0.28-1.54)	0.93
No. of case patients/no. of control subjects	20/44	17/57	25/57	23/51	
Multivariate OR‡ 6 y lag time	1.00 (Reference)	0.46 (0.18-1.14)	0.68 (0.28-1.64)	0.75 (0.29-1.92)	0.79
No. of case patients/no. of control subjects	19/40	16/51	22/47	16/46	
Multivariate OR‡ 7 y lag time	1.00 (Reference)	0.43 (0.16-1.17)	0.53 (0.19-1.47)	0.38 (0.13-1.11)	0.13
No. of case patients/no. of control subjects	18/31	15/46	18/39	12/36	
Multivariate OR‡ 8 y lag time	1.00 (Reference)	0.25 (0.07-0.90)	0.29 (0.07-1.10)	0.17 (0.04-0.71)	0.01

*We tested for trends by modeling aMT6s concentrations continuously and calculating the Wald statistic.

†Simple conditional logistic regression model adjusting for the matching variables [year of birth, month and year of urine collection, and laboratory batch].

‡Multivariate conditional logistic regression models; relative risks were adjusted for the following breast cancer risk factors: BMI in six categories (≤21, 21.1-23, 23.1-25, 25.1-27, 27.1-30, >30), history of benign breast disease (yes/no), family history (mother or sister) of breast cancer (yes/no), smoking history (never, past, current), age at menarche in four categories (≤12, 13, 14, 15+), alcohol consumption per day in grams, three categories (none, ≤12, >12), years of oral contraceptive use (never, ≤1 y, >1 y), parity in three categories (nulliparous, 1-2, 3+ children), age at first birth in three categories (<20, 20-24, ≥25), and participant's educational status in years of schooling, three categories [≤5 y (elementary school), 8 y (superior education), >8 y].

also correlated well with crude aMT6s concentration ($r = 0.61$ and 0.73 , respectively, both $P < 0.001$). In multivariate analyses, we observed a positive association between creatinine-adjusted urinary aMT6s and invasive breast cancer risk (OR for highest versus lowest quartile of total urinary aMT6s, 1.67; 95% CI, 0.99-2.82; $P_{\text{trend}} = 0.27$), a risk which was also markedly attenuated among never and past smokers (highest versus lowest quartile of creatinine-adjusted urinary aMT6s, 1.21; 95% CI, 0.65-1.25; $P_{\text{trend}} = 0.98$).

Urinary creatinine concentration is influenced by several factors including gender, ethnicity, age and BMI (33). Although our study was exclusively composed of Caucasian women, differences in age and BMI may have biased our creatinine-adjusted aMT6s measure. There was only a modest correlation between creatinine-adjusted aMT6s and creatinine (Spearman $r = -0.15$, $P < 0.001$), suggesting the potential for bias introduced by adjusting for creatinine to be small.

Discussion

Overall, we found a positive association between overnight urinary aMT6s and breast cancer risk. However, we found a significant inverse association between overnight urinary aMT6s and breast cancer risk in premenopausal women, but only in nonsmokers and after allowing for sufficient (8 year) lag time between urine collection and the diagnosis of breast cancer. These findings suggest that there might be an influence of subclinical disease on melatonin levels with a possible inverse association being seen among women diagnoses further from recruitment.

Few prior studies have evaluated the association between circulating melatonin levels and breast cancer risk in humans and most are limited by the fact that melatonin levels were measured after the subjects were diagnosed with breast cancer (6, 31, 34-43). The first report to evaluate an association between circulating melatonin levels and breast cancer risk in 10 women was conducted by Bartsch et al. in 1981 (36). It found in a small sample of women with advanced breast cancer, when compared with healthy controls, that they had lower levels of urinary melatonin (36). Subsequently, Tamarkin et al. (31) found that women with ER-positive breast cancer had a reduced nocturnal increase in melatonin, and observed an inverse correlation between ER levels and peak melatonin values. Several subsequent studies examined melatonin levels in cancer patients (6, 31, 34-43). Because blood samples for melatonin were typically collected after a diagnosis of cancer in these retrospective studies, they are limited in their ability to assess the predictive value of the hormone for breast cancer risk. However, data from nontreated patients with localized breast cancer provide evidence for a depression of the nocturnal surge of melatonin that parallels an increase in tumor size and the development of distant metastases (34, 35, 37). Together with evidence from nontreated primary prostate cancer patients, in which melatonin levels were particularly high if well-differentiated G1 (incidental) carcinomas were present (44), these observations suggest complex interactions between the pineal gland and tumor growth. Melatonin has a potential role in different phases of carcinogenesis such as initial activation, inhibition of tumor growth, and restimulation as cancer cells disseminate; this complexity may account for apparent inconsistencies found in prospective studies.

More recently, evidence from prospective case-control studies nested in larger cohorts has been published. An Italian case-control study nested within the ORDET cohort assessed the concentration of the major metabolite of melatonin, aMT6s, in 178 postmenopausal women with incident invasive breast cancer and 710 matched controls. The multivariate relative risk for women in the highest quartile of total overnight aMT6s output compared with the lowest was 0.56 (95% CI, 0.33-0.97). In this report, overnight urinary aMT6s level and breast cancer risk were more strongly associated in women who were diag-

nosed with invasive breast cancer >4 years after urine collection (OR, 0.34 highest versus lowest quartile; 95% CI, 0.15-0.75; ref. 45). A second case-control study in postmenopausal women was conducted nested within the NHS cohort (17). In that study, aMT6s levels were available for 357 postmenopausal women who developed incident breast cancer along with 533 matched control subjects. An increased concentration of urinary aMT6s was statistically significantly associated with a lower risk of breast cancer with an OR for the highest versus lowest quartile of morning urinary aMT6s of 0.62 (95% CI, 0.41-0.95; $P_{\text{trend}} = 0.004$).

Evidence for an association between urinary melatonin and breast cancer risk among premenopausal women is also sparse and has been less consistent, perhaps in part due to varying urine sampling methods used in these studies. Only two prospective studies have evaluated the associations, one of which did not find an increased risk (19), whereas the other one described a significantly reduced risk of breast cancer risk in women with the highest melatonin levels. In the first study, a prospective study of urinary 6MTs in 77 cases and 214 premenopausal controls matched for age, recruitment date, day of menstrual cycle, the OR for breast cancer was 0.99 (95% CI, 0.45-2.17), comparing the highest to the lowest category (19). This study used 24-hour urine collection, in contrast to the NHS II, which used first-morning urine samples (20). The use of 24-hour urine may decrease the power to detect potential differences by case-control status, but the confidence limits of this study do not preclude an effect of melatonin on breast cancer risk. Moreover, no lag time analyses were conducted in this study. In the NHS II cohort, finally, aMT6s levels were measured in the first-morning urine of 147 women with invasive breast cancer and 291 matched control subjects. The OR for women in the highest quartile of urinary aMT6s was 0.59 compared with those in the lowest quartile, and remained unchanged after adjusting for several important confounding factors (46). A meta-analysis of all five (including ours, excluding cases that were diagnosed within 2 years after urine collection) prospective studies published, to date, suggests a 34% significant risk reduction of breast cancer with the highest category of aMT6s (Fig. 1).

We were able to consider most important breast cancer risk factors in our analyses. Excluding cases diagnosed with increasing years after urine collection altered our findings; we observed increasingly stronger risk reductions with longer time between urine collection and breast cancer diagnosis, suggesting that perhaps particularly in premenopausal women, their typically more rapid and aggressive tumor growth that is in part attributable to differences in the prevalence of molecular breast cancer subtypes (47) may mask the predictive power of aMT6s for breast cancer risk as it also seems to constitute a marker for tumor growth. Alternatively, because those women in whom we observed the strongest associations were in large part postmenopausal at the time of diagnosis, this could either argue for a stronger effect of melatonin on breast tumors with features more commonly




Figure 1. Meta-analysis of five prospective studies examining the associations between urinary melatonin secretion and breast cancer risk. Dashed vertical line, the combined estimate; diamond-shaped box, the CI from the random-effects model. The estimates are plotted with boxes; the area of each box is inversely proportional to the estimated effect's variance in the study, hence giving more visual prominence to studies in which the effect is more precisely estimated.

seen in postmenopause (that is, hormone receptor status, histology) or for a role of change in menopausal status. The apparent need to lag time between specimen collection and breast cancer diagnosis may, in addition to varying urine sampling methods (that is, 24-hour versus overnight urine), explain the null finding in one (19) of the other two studies describing the association between melatonin and breast cancer risk in premenopausal women.

Although we did not observe a significant interaction between smoking and aMT6s levels in this data set, it is similar in magnitude and direction as in a previous analysis (48) and further underlines the necessity to consider that various external influences including metabolism rate, possibly altered by smoking (49, 50), can influence a urinary marker such as aMT6s.

Our study is limited by the absence of information on light exposure at night including night work status; thus, we cannot adjust for this factor. Another potential limitation of our study is that we did not have information on vitamin D status in our study subjects, another possible

breast cancer risk factor (51, 52). The relationship between melatonin levels and vitamin D is unclear, but if one exists, it could have influenced our results. For example, it is conceivable that women with low morning melatonin levels (if due to an altered sleep-wake cycle) also have particularly low levels of vitamin D mediated by low sun exposure or differences in dietary habits.

Our findings show that melatonin secretion, as assessed by aMT6s levels in 12-hour overnight urine, is associated with a reduced risk of developing premenopausal breast cancer but only if long enough lag times are applied. Thus, although evidence for an association between melatonin and breast cancer risk continues to accumulate, further studies are needed to evaluate the influence of lag time on the association between melatonin and breast cancer risk. These studies should have long enough follow-up to address the time between urine collection (as an apparently healthy person) and cancer diagnosis, as it is conceivable that melatonin secretion is stimulated during early subclinical stages of tumor development.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank the 10,786 ORDET participants, Dr. P. Crosignani and the staff of the Lombardy Cancer Registry for the technical assistance, C. Agnoli for the statistical support, Dr. D. Morelli for conducting the creatinine assays, and Drs. G. Bolelli and F. Franceschetti for conducting the sex steroid assays.

Grant Support

Department of Defense grant W81 XWH 04 1 0195 and National Cancer Institute grant CA98344.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 12/07/2009; revised 01/14/2010; accepted 01/15/2010; published OnlineFirst 03/02/2010.

References

- Arendt J. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. *Rev Reprod* 1998;3:13–22.
- Czeisler CA, Klerman EB. Circadian and sleep-dependent regulation of hormone release in humans. *Recent Prog Horm Res* 1999;54:97–130.
- Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. *Science* 1999;284:2177–81.
- Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. *J Clin Endocrinol Metab* 1985;60:1166–73.
- Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. *J Pineal Res* 1998;24:58–61.
- Cook MR, Graham C, Kavet R, Stevens RG, Davis S, Kheifets L. Morning urinary assessment of nocturnal melatonin secretion in older women. *J Pineal Res* 2000;28:41–7.
- Lang U, Kornemark M, Aubert ML, Paunier L, Sizonenko PC. Radio-immunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. *J Clin Endocrinol Metab* 1981;53:645–50.
- Leibenluft E, Feldman-Naim S, Turner EH, Schwartz PJ, Wehr TA. Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder. *Biol Psychiatry* 1996;40:731–5.
- Nowak R, McMillen IC, Redman J, Short RV. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. *Clin Endocrinol* 1987;27:445–52.

10. Wetterberg L. Melatonin in humans physiological and clinical studies. *J Neural Transm Suppl* 1978;13:289–310.
11. Schernhammer ES, Hankinson SE. Light at night: a novel risk factor for cancer in shift workers? *Clin Occup Environ Med* 2003;3:263–78.
12. Stevens RG, Blask DE, Brainard GC, et al. Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. *Environ Health Perspect* 2007;115:1357–62.
13. Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. *Lancet* 1978;2:814–6.
14. Brzezinski A. Melatonin in humans. *N Engl J Med* 1997;336:186–95.
15. Vijayalaxmi, Thomas CR, Jr., Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. *J Clin Oncol* 2002;20:2575–601.
16. Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. *Cancer Res* 2005;65:11174–84.
17. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk in the Nurses' Health Study cohort. *Cancer Epidemiol Biomarkers Prev* 2009;18:74–9.
18. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst* 2008;100:898–905.
19. Travis RC, Allen DS, Fentiman IS, Key TJ. Melatonin and breast cancer: a prospective study. *J Natl Cancer Inst* 2004;96:475–82.
20. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. *J Natl Cancer Inst* 2005;97:1084–7.
21. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. *J Natl Cancer Inst* 1996;88:291–6.
22. Berrino F, Pisani P, Muti P. Prospective study of hormones and diet in the aetiology of breast cancer. In: Riboli E, Saracci R, editors. *Diet, hormones, and cancer: methodological issues for prospective studies* IARC Technical Report Number 4. Lyon: IARC; 1988, p. 34–38.
23. Parkin DM, Whelan S, Ferlay J. *Cancer Incidence in five continents*, vol. VII. IARC Scientific Publications Number 143. Lyon: IARC; 1997.
24. Waterhouse J, Muir C, Shanmugaratnam K. *IARC Scientific Publications*. Lyons: IARC; 1982.
25. Barba M, Cavalleri A, Schunemann HJ, et al. Reliability of urinary 6-sulfatoxymelatonin as a biomarker in breast cancer. *Int J Biol Markers* 2006;21:242–5.
26. Bartels H, Bohmer M, Heierli C. [Serum creatinine determination without protein precipitation]. *Clin Chim Acta* 1972;37:193–7.
27. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. *Biometrics* 1988;44:1049–60.
28. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. *J Natl Cancer Inst* 2001;93:1563–8.
29. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. *J Natl Cancer Inst* 2001;93:1557–62.
30. Hansen J. Increased breast cancer risk among women who work predominantly at night. *Epidemiology* 2001;12:74–7.
31. Tamarkin L, Danforth D, Lichter A, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. *Science* 1982;216:1003–5.
32. Schernhammer ES, Kroenke CH, Dowsett M, Folkert E, Hankinson SE. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. *J Pineal Res* 2006;40:116–24.
33. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. *Environ Health Perspect* 2005;113:192–200.
34. Bartsch C, Bartsch H, Bellmann O, Lippert TH. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. *Cancer* 1991;67:1681–4.
35. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. correlation with prolactin, thyroid stimulating hormone, and steroid receptors. *Cancer* 1989;64:426–33.
36. Bartsch C, Bartsch H, Jain AK, Laumas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. *J Neural Transm* 1981;52:281–94.
37. Bartsch C, Bartsch H, Karenovics A, Franz H, Peiker G, Mecke D. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. *J Pineal Res* 1997;23:53–8.
38. Danforth DNJ, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME. Plasma melatonin and the hormone-dependency of human breast cancer. *J Clin Oncol* 1985;3:941–8.
39. Falkson G, Falkson HC, Steyn ME, Rapoport BL, Meyer BJ. Plasma melatonin in patients with breast cancer. *Oncology* 1990;47:401–5.
40. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. *J Pineal Res* 1998;24:230–8.
41. Lissoni P, Bastone A, Sala R, et al. The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. *Eur J Cancer Clin Oncol* 1987;23:949–57.
42. Lissoni P, Crispino S, Barni S, et al. Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. *Oncology* 1990;47:275–7.
43. Skene DJ, Bojkowski CJ, Currie JE, Wright J, Boulter PS, Arendt J. 6-Sulphatoxymelatonin production in breast cancer patients. *J Pineal Res* 1990;8:269–76.
44. Bartsch C, Bartsch H, Fluchter SH, Attanasio A, Gupta D. Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones. *J Pineal Res* 1985;2:121–32.
45. Schernhammer E, Berrino F, Krogh V, et al. Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in postmenopausal women: the ORDET cohort. *J Natl Cancer Inst* 2008;100:898–905.
46. Schernhammer E, Kroenke C, Laden F, Hankinson S. *Night Work and Melatonin Levels in Women Participating in the Nurses' Health Study II: Associate with Breast Cancer Risk*. 2nd Symposium of the Dana-Farber/Harvard Cancer Center Program in Breast Cancer, Boston. 2005.
47. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. *Clin Breast Cancer* 2009;9 Suppl 2:S73–81.
48. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. *Cancer Epidemiol Biomarkers Prev* 2009;18:74–9.
49. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? *Basic Clin Pharmacol Toxicol* 2005;97:125–34.
50. Hartter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. *Br J Clin Pharmacol* 2003;56:679–82.
51. Welsh J. Vitamin D and breast cancer: insights from animal models. *Am J Clin Nutr* 2004;80:1721S–4S.
52. Zhang SM. Role of vitamins in the risk, prevention, and treatment of breast cancer. *Curr Opin Obstet Gynecol* 2004;16:19–25.

Cancer Epidemiology, Biomarkers & Prevention

AACR American Association
for Cancer Research

Urinary 6-Sulphatoxymelatonin Levels and Risk of Breast Cancer in Premenopausal Women: The ORDET Cohort

Eva S. Schernhammer, Franco Berrino, Vittorio Krogh, et al.

Cancer Epidemiol Biomarkers Prev 2010;19:729-737. Published OnlineFirst March 3, 2010.

Updated version Access the most recent version of this article at:
doi:[10.1158/1055-9965.EPI-09-1229](https://doi.org/10.1158/1055-9965.EPI-09-1229)

Cited articles This article cites 48 articles, 9 of which you can access for free at:
<http://cebp.aacrjournals.org/content/19/3/729.full#ref-list-1>

Citing articles This article has been cited by 9 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/19/3/729.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cebp.aacrjournals.org/content/19/3/729>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.